An international expert panel discusses POCT related to COVID-19 severity assessment and risk prediction, plus covers the role of POCT in antimicrobial resistance during the pandemic, in this video seminar originally delivered live on 4 September 2020. Hear from Professor Nicholas Francis (UK), Professor Ivan Gentile (Italy), Dr Carl Llor (Spain), Professor Dag Berild (Norway) and Dr Aggy York (UK) by clicking here.
Hear expert opinion on the use of CRP POCT for COVID-19 management and reduction of antimicrobial resistance
This on-demand seminar recording features expert panel discussion on the importance of C-reactive protein (CRP) point-of-care testing (POCT) related to COVID-19.
The seminar presents studies from around the world indicating that CRP levels are a valuable inflammatory marker for severity and risk assessment in COVID-19 patients.
The session also covers the importance of antibiotic stewardship programmes in the context of the global pandemic and looks at the recent findings from the PACE study, which investigated CRP POCT as a guide for antibiotic prescribing in acutely exacerbated chronic obstructive pulmonary disease (COPD).
See below for a list of our renowned expert panel and a summary of the programme:
- Professor Nicholas Francis (UK)
- Professor Ivan Gentile (Italy)
- Speaker: Severity assessment and outcome prediction in the COVID-19 patients
- Dr Carl Llor
- Speaker: The emergence of multi-resistance associated with the overuse of antibiotics during COVID-19 pandemic
- Professor Dag Berild (Norway)
- Speaker: Antimicrobial stewardship in the time of COVID-19 is vital – AMR still persists and could be heightened by the pandemic
- Dr Aggy York (UK)
To read the learning objectives for this session, plus watch the seminar in full, please click here.
The views and opinions presented are of the author only. The content contained in this webcast is intended for informational / educational purposes only.
© 2022 Abbott. Todos los derechos reservados. Todas las marcas comerciales a las que se hace referencia son marcas comerciales del grupo de empresas Abbott o de sus respectivos propietarios.
The Kidney Disease: Improving Global Outcomes (KIDGO) 2022 clinical practice guidelines are based on a systematic review of evidence and aim to assist health care professionals with their decision making for people with diabetes and chronic kidney disease (CKD). The authors highlight that by 2045, 784 million people are estimated to have diabetes globally, of whom ≥40% will develop CKD, potentially leading to kidney failure requiring dialysis or ...
KIDGO clinical practice guidelines: diabetes management in chronic kidney diseaseenAcceder ya
The objective of this longitudinal cohort study was to determine the prevalence of chronic kidney disease (CKD) and associated risk factors in a rural South African population. The authors note that infectious and non-communicable disease are a substantial risk for CKD in Africa, but that heterogeneity in assessment and diagnostic criteria hamper the interpretation of prevalence.
Chronic kidney disease prevalence and risks in rural South AfricaenAcceder ya
The objective of this cross-sectional, primary care analysis in adults with chronic kidney disease (CKD) was to investigate the association between albuminuria testing and the likelihood of receiving nephrology care. The authors note that measurement of both estimated glomerular filtration rate (eGFR) and albuminuria (urine albumin-creatinine ratio) are necessary for effective risk stratification for CKD, but that albuminuria testing remains wide...
Albuminuria testing in adults with chronic kidney diseaseenAcceder ya